Gemcitabine

Generic Name
Gemcitabine
Brand Names
Gemzar
Drug Type
Small Molecule
Chemical Formula
C9H11F2N3O4
CAS Number
95058-81-4
Unique Ingredient Identifier
B76N6SBZ8R
Background

Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication

Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions
Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

First Posted Date
2024-06-12
Last Posted Date
2024-06-12
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
19
Registration Number
NCT06454383
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

First Posted Date
2024-06-07
Last Posted Date
2024-12-17
Lead Sponsor
BioNTech SE
Target Recruit Count
70
Registration Number
NCT06449222
Locations
🇺🇸

Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States

🇺🇸

Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States

🇺🇸

Bozeman Health Deaconess Hospital Cancer Center, Bozeman, Montana, United States

and more 32 locations

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

First Posted Date
2024-06-06
Last Posted Date
2024-06-06
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
360
Registration Number
NCT06446388
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

First Posted Date
2024-06-06
Last Posted Date
2024-12-19
Lead Sponsor
Revolution Medicines, Inc.
Target Recruit Count
406
Registration Number
NCT06445062
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

UCLA Hematology/Oncology- Santa Monica, Los Angeles, California, United States

🇺🇸

University of Colorado Hospital-Anschutz Cancer Pavilion, Aurora, Colorado, United States

and more 14 locations

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

First Posted Date
2024-06-04
Last Posted Date
2024-06-04
Lead Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Target Recruit Count
42
Registration Number
NCT06440993
Locations
🇩🇪

Krankenhaus Nordwest, Frankfurt, Germany

🇩🇪

Universitätsklinikum Düsseldorf, Düsseldorf, Germany

🇩🇪

Universitätsklinikum Köln, Köln, Germany

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

First Posted Date
2024-05-30
Last Posted Date
2024-12-18
Lead Sponsor
Jazz Pharmaceuticals
Target Recruit Count
550
Registration Number
NCT06435429
Locations
🇺🇸

USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS, Los Angeles, California, United States

🇺🇸

Medstar Georgetown University Hospital, Washington, District of Columbia, United States

🇺🇸

Washington Cancer Center, Washington, District of Columbia, United States

and more 38 locations

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

First Posted Date
2024-05-21
Last Posted Date
2024-08-14
Lead Sponsor
Emory University
Target Recruit Count
44
Registration Number
NCT06423326
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

First Posted Date
2024-05-20
Last Posted Date
2024-05-20
Lead Sponsor
Jinghui Wang
Target Recruit Count
30
Registration Number
NCT06421298
Locations
🇨🇳

Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

First Posted Date
2024-05-03
Last Posted Date
2024-07-19
Lead Sponsor
OHSU Knight Cancer Institute
Registration Number
NCT06398587
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC)

First Posted Date
2024-05-01
Last Posted Date
2024-05-07
Lead Sponsor
John Lenehan
Target Recruit Count
20
Registration Number
NCT06393400
Locations
🇨🇦

Verspeeten Family Cancer Centre (formerly known as the London Regional Cancer Program) London Health Sciences Centre, London, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy